{
    "2021-03-26": [
        [
            {
                "time": "2021-03-26",
                "original_text": "西南证券维持贝达药业持有评级：业绩维持高速增长，公司逐渐进入收获期",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "持有评级",
                        "业绩增长",
                        "收获期"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-03-26",
                "original_text": "贝达药业(300558)：2020完美收官 2021值得期待 从1到多新征程开启",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "2020年",
                        "完美收官",
                        "2021年",
                        "新征程"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-03-26",
                "original_text": "国盛证券维持贝达药业买入评级：2020完美收官，2021值得期待，从1到多新征程开启",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "买入评级",
                        "2020年",
                        "完美收官",
                        "2021年",
                        "新征程"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-03-26",
                "original_text": "每日“药”闻|蓝帆医疗商誉减值17.6亿；多家药企公布业绩，先声药业利润下滑34%",
                "features": {
                    "keywords": [
                        "蓝帆医疗",
                        "商誉减值",
                        "药企",
                        "业绩",
                        "先声药业",
                        "利润下滑"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-03-26",
                "original_text": "国金证券-贝达药业:埃克替尼放量，恩沙替尼接棒，多药上市中【公司研究】",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "埃克替尼",
                        "恩沙替尼",
                        "多药上市"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-03-26",
                "original_text": "上市公司正负面新闻2021年3月26日星期五",
                "features": {
                    "keywords": [
                        "上市公司",
                        "正负面新闻"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-03-26",
                "original_text": "贝达药业：2020年盈利6.06亿元，同比增长162.79%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "2020年",
                        "盈利",
                        "同比增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}